Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma

Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma

Abstract A limited number of patients with lung squamous cell carcinoma (SCC) benefit clinically from molecular targeted drugs because of a lack of targetable driver alterations. We aimed to understand the prevalence and clinical significance of lysine‐specific demethylase 5D (KDM5D) copy number los...

Full description

Bibliographic Details
Main Authors: Ayako Ura, Takuo Hayashi, Kazumasa Komura, Masaki Hosoya, Kazuya Takamochi, Eiichi Sato, Satomi Saito, Susumu Wakai, Takafumi Handa, Tsuyoshi Saito, Shunsuke Kato, Kenji Suzuki, Takashi Yao, the Tokyo Metropolitan Innovative Oncology Research Group (TMIG)
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:The Journal of Pathology: Clinical Research
Subjects:
ataxia‐telangiectasia and Rad3‐related kinase
DNA damage response
KDM5D
squamous cell carcinoma
Online Access:https://doi.org/10.1002/cjp2.350

Internet

https://doi.org/10.1002/cjp2.350

Similar Items